Combination therapies are being explored to improve immunotherapy efficacy in pMMR/MSS metastatic colorectal cancer (mCRC) patients, who do not typically respond well to single-agent immune checkpoint inhibitors.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.